首页> 外文期刊>Universal Journal of Public Health >Delay in the Provision of Antiretroviral Therapy to HIV-infected TB Patients in Nigeria
【24h】

Delay in the Provision of Antiretroviral Therapy to HIV-infected TB Patients in Nigeria

机译:尼日利亚向艾滋病毒感染的结核病患者推迟提供抗逆转录病毒疗法

获取原文
           

摘要

Background: Nigeria has a high burden of HIV and tuberculosis (TB). To reduce TB-associated morbidity and mortality, the World Health Organization recommends that HIV-positive TB patients receive antiretroviral therapy (ART) within eight weeks of TB treatment initiation, or within two weeks if profoundly immunosuppressed (CD4<50 cell/μL). Methods: TB and HIV clinical records from facilities in two Nigerian states between October 1~(st), 2012 and September 30~(th), 2013 were retrospectively reviewed to assess uptake and timing of ART initiation among HIV-positive TB patients. Healthcare workers were qualitatively interviewed to assess TB/HIV knowledge and barriers to timely ART. Results: Data were abstracted from 4,810 TB patient records, of which 1,249 (26.0%) had HIV-positive or unknown HIV status documented, and the 574 (45.9%) HIV-positive TB patients were evaluated for timing of ART uptake relative to TB treatment. Among 484 (84.3%) HIV-positive TB patients not already on ART, 256 (52.9%, 95% CI: 45.0-60.8) were not initiated on ART during six months of TB treatment. 30.0% of 273 patients with a known CD4≥50cells/μL started ART within eight weeks, and 14.8% of 54 patients with a known CD4<50cells/μL started within the recommended two weeks. Only 42% of health workers interviewed reported knowing to interpret guidelines on when to initiate ART in HIV-positive TB patients based on CD4 cell count results. CD4 cell count significantly predicted timely ART uptake. Conclusion: A large proportion of HIV-positive TB patients were not initiated on ART early or even at all during TB treatment. Retraining of staff, and interventions to strengthen referral systems should be implemented to ensure timely provision of ART among HIV-positive TB patients in Nigeria.
机译:背景:尼日利亚的艾滋病毒和结核病负担很高。为了降低与结核病相关的发病率和死亡率,世界卫生组织建议艾滋病毒阳性的结核病患者在开始结核病治疗后的八周内或如果受到强烈的免疫抑制(CD4 <50细胞/μL),则应在两周内接受抗逆转录病毒疗法(ART)。方法:回顾性分析2012年10月1日至2013年9月30日在尼日利亚两个州的设施中进行的结核病和艾滋病毒临床记录,以评估HIV阳性结核病患者开始接受ART的时间和时间。对医护人员进行了定性访谈,以评估结核病/艾滋病知识和及时抗病毒治疗的障碍。结果:从4,810 TB病人记录中提取数据,其中1,249(26.0%)记录有HIV阳性或未知状态,并评估了574(45.9%)HIV阳性结核病患者相对于TB的ART摄取时间治疗。在484名(84.3%)尚未接受抗病毒治疗的HIV阳性结核病患者中,有256名(52.9%,95%CI:45.0-60.8)在接受结核病治疗的六个月内未开始抗病毒治疗。在273名CD4≥50个细胞/μL的患者中,有30.0%的患者在8周内开始ART;在54例CD4 <50cells /μL的患者中,有14.8%的患者在推荐的两周内开始了ART。接受采访的卫生工作者中只有42%表示知道会根据CD4细胞计数结果解释何时对HIV阳性结核病患者发起抗逆转录病毒治疗的指南。 CD4细胞计数显着预测了适时的ART摄取。结论:很大一部分HIV阳性结核病患者在结核病治疗期间甚至早期根本没有开始抗病毒治疗。应实施人员再培训以及加强转诊系统的干预措施,以确保在尼日利亚的HIV阳性结核病患者中及时提供抗病毒治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号